8-K: Genprex Announces 1-for-40 Reverse Stock Split to Regain Nasdaq Compliance

Genprex, Inc. has announced a 1-for-40 reverse stock split, effective February 2, 2024, to increase its stock price and regain compliance with Nasdaq's minimum bid requirement.

Summary

• Genprex, Inc. has filed a Certificate of Amendment to enact a 1-for-40 reverse stock split of its common stock.
• The reverse stock split will be effective at 12:01 a.m. Eastern Time on February 2, 2024.
• Every 40 shares of existing common stock will be combined into one new share.
• The company's stock will begin trading on a split-adjusted basis on February 2, 2024.
• The reverse stock split is intended to increase the market price per share to meet Nasdaq's minimum bid requirement.
• The CUSIP number for the common stock will change to 372446-203.
• No fractional shares will be issued; instead, fractional shares will be rounded up to the nearest whole share.
• The reverse stock split will not change the par value of the common stock or the authorized number of shares.
• All outstanding securities, such as stock options and warrants, will be adjusted accordingly.
• The company anticipates having approximately 1.5 million shares of common stock issued and outstanding after the split.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the need for a reverse stock split, which is typically a sign of a struggling stock price. However, the company is taking action to address the issue.

Positives

• The reverse stock split is a strategic move to regain compliance with Nasdaq listing requirements.
• Rounding up fractional shares ensures that no shareholder loses out due to the split.
• The company is taking proactive steps to address its stock price.

Negatives

• The reverse stock split is often a sign of a struggling stock price.
• The need for a reverse stock split indicates that the company's stock price has fallen below the minimum bid requirement of the Nasdaq Capital Market.

Risks

• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements.
• The company's stock price may continue to decline even after the reverse stock split.
• The company's future success depends on the clinical development and commercialization of its product candidates.

Future Outlook

The company's future success depends on the clinical development and commercialization of its product candidates, as well as maintaining compliance with Nasdaq listing requirements. The company is also focused on obtaining capital to meet its long-term liquidity needs.

Management Comments

• The Board approved implementation of the reverse stock split upon the authorization granted by the Companys stockholders at the special meeting held on December 14, 2023.

Industry Context

Reverse stock splits are often used by companies to avoid delisting from exchanges when their stock price falls below minimum requirements. This action is not uncommon in the biotech industry, where companies may face challenges in maintaining stock prices during the development phase of their products.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from exchanges due to low share prices, particularly in the biotech sector.
• Many small-cap biotech companies, such as those in the clinical trial phase, have used reverse stock splits to maintain their listing status.
• The 1-for-40 ratio is within the range of reverse stock splits seen in the industry, although some companies have used more extreme ratios.
• Companies like Agenus Inc. (AGEN) and Ocugen, Inc. (OCGN) have also recently implemented reverse stock splits to maintain Nasdaq compliance.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares which will be rounded up.
• The reverse stock split is intended to help the company maintain its Nasdaq listing, which is important for investor confidence.

Next Steps

• The company's common stock will begin trading on a split-adjusted basis on February 2, 2024.
• The company will continue to focus on the clinical development and commercialization of its product candidates.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, common stock, stock price, Genprex, GNPX, shareholders, listing requirements